Special lssues

Advances in Cancer Therapeutics

Submission Deadline: 31 December 2023 (closed)

Guest Editors

Prof. Dr. Riffat Mehboob, Lahore Medical Research Center, Lahore, Pakistan. E-mail: mehboob.riffat@gmail.com

Prof. Dr. Fridoon Jawad Ahmad, University of health sciences, Lahore, Pakistan. E-mail: drfridoon@yahoo.com

Prof. Dr. Imrana Tanvir, Faculty of Medicine in Rabigh, Rabigh, Saudi Arabia. E-mail: imrana_tanvir@yahoo.com

Prof. Dr. Muhammad Akram Tariq, Mirpur University of Science and Technology, Pakistan. E-mail: akram@soe.ucsc.edu

Summary

Cancer is the leading cause of worldwide mortalities. Its treatment has always remained challenging due to its complicated aetiology, underlying mechanisms, several pathways controlling the same disease causing gene, complex genetics and influence of environmental factors. Although a great advancement in medicine has led to better management of cancer, improved diagnostics and therapies, still a lot needs to be done in this regard. Prevalence and deaths have been on an increasing verge despite all the collective efforts. Latest technologies such as gene therapy, extracellular vesicles, nanotechnology has revolutionized the cancer treatment.

In this issue we will publish studies related to all kind of therapeutic strategies to understand where are we standing now! Original articles, experimental studies, clinical studies, review articles, opinion articles are welcome.

 

Articles in these areas or related to therapies are encouraged.

 

-Targeting Cancer metabolism for cancer therapy

-Targeting the proliferative markers such as Ki67 as cancer therapy

-Mammalian target of Rapamycin (mTOR) as a potential therapeutic strategy

-Novel Peptide biomarkers in cancer diagnostics and therapy

-Natural products in cancer therapy

-Extacellular vesicles/exosomes as diagnostic and therapeutic tool in cancer

-Bacteria mediated cancer therapy

-Prodrugs in cancer therapy

-drug repurposing in cancer therapy

-Nanotechnology in cancer therapy

-Gene editing/ CRISPR-Cas9 in cancer therapy


Keywords

Cancer therapy, Biomarkers, Gene editing,Nanotechnology

Published Papers


  • Open Access

    ARTICLE

    Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells

    ROGHAYEH GHORBANI, MAHMOUD GHARBAVI, ALI SHARAFI, ELHAM RISMANI, HAMED REZAEEJAM, YOUSEF MORTAZAVI, BEHROOZ JOHARI
    Oncology Research, Vol.32, No.1, pp. 101-125, 2024, DOI:10.32604/or.2023.044741
    (This article belongs to this Special Issue: Advances in Cancer Therapeutics)
    Abstract In the present study, we investigated the synergistic effects of targeted methotrexate-selenium nanostructure containing Myc decoy oligodeoxynucleotides along with X-irradiation exposure as a combination therapy on LNCaP prostate cancer cells. Myc decoy ODNs were designed based on the promoter of Bcl-2 gene and analyzed by molecular docking and molecular dynamics assays. ODNs were loaded on the synthesized Se@BSA@Chi-MTX nanostructure. The physicochemical characteristics of nanostructures were determined by FTIR, DLS, UV-vis, TEM, EDX, in vitro release, and hemolysis tests. Subsequently, the cytotoxicity properties of them with and without X-irradiation were investigated by uptake, MTT, cell cycle, apoptosis, and scratch assays on… More >

    Graphic Abstract

    Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells

Share Link